Sublicensing Revenue. In the event that MorphoSys enters into a Sublicense prior to […***…] for a Licensed Product covered by the Sublicense, but subject to Section 3.3(b), MorphoSys shall pay to Xencor […***…] ([…***…] %) of all Sublicensing Revenue. Notwithstanding the foregoing, in the event that MorphoSys enters into a Sublicense […***…] or later after the Effective Date, an amount of […***…] US Dollars ($ […***…]) shall be deducted from […***…] received by MorphoSys from Sublicensee before calculating Xencor’s share of Sublicensing Revenue due under this Section 5.3. For the purpose of this Section, a Sublicense is deemed granted the date it is committed to in a legally binding way, including in the case of an option for a Sublicense, the date the legally binding document granting the option is signed or otherwise becomes effective. For amounts of consideration for Sublicense paid to MorphoSys or its Affiliates by its Sublicensees, which amounts are received for achievement of the milestone events set forth in Section 5.2, to the extent that MorphoSys actually pays such amounts to Xencor pursuant to Section 5.2, the Milestone Payments according to Sec. 5.2 hereof shall be deducted from […***…] before calculating Xencor’s share of Sublicensing Revenue due under this Section. The percentage of Sublicensing Revenue is due to Xencor after MorphoSys or its Affiliate receives the underlying Sublicensing Revenue and. MorphoSys shall inform Xencor about the receipt of any Sublicensing Revenue and shall make the respective payment to Xencor within […***…] of such receipt.
Sublicensing Revenue. “Sublicensing Revenue” shall mean [***]. Sublicensing Revenues shall exclude: [***].
Sublicensing Revenue. In addition to the foregoing, Licensee shall pay KeyGene [***]% of all Licensee or its Affiliates’ Sublicense Revenues. Licensee, its Affiliates, and Sublicensees are prohibited from [***]. In the event of a consideration for a Sublicense or cross license that is non-monetary the Sublicense Revenue shall be calculated based on the fair market value of such consideration. KeyGene’s share of any Sublicense Revenues shall be due within [***] of the entry of a sublicense agreement or the occurrence of an event that triggers a payment in favor of Licensee.
Sublicensing Revenue. In the event King enters into an agreement sublicensing to a Third Party the rights and licenses granted to it pursuant to Section 2.1 hereof to Develop, Market, distribute, offer for sale, sell, import or otherwise commercialize Products in the ROW, King shall pay to PTI [***] of all up-front, milestones and other economic consideration received by King from such Third Party in exchange for the grant of such rights, which up-front, milestones and other payments shall be subject to Sections 6.2, 6.3 and 6.4 hereof.
Sublicensing Revenue. Licensee shall pay to Salk, in accordance with Section 9.2, a portion of all Sublicensing Revenue received by Licensee during the Term of this Agreement, as follows:
Sublicensing Revenue. IMDZ shall pay to TVS an amount equal to [*] of Sublicensing Revenue for each [*]. Such royalties on Sublicensing Revenue shall be paid to TVS concurrently with the submittal of Royalty Reports as provided in Section 4.2 below. 3.6
Sublicensing Revenue. Licensee shall pay to Licensor fifty percent (50%) of Licensee’s Sublicensing Revenues within forty-five (45) days of Licensee’s receipt thereof.
Sublicensing Revenue. The remuneration received under each Sublicense, including without limitation the fair market cash value of any and all non-cash consideration, including without limitation license issue fees, option fees, other licensing fees, milestone payments, minimum annual royalties, equity, or other payments of any kind whatsoever (but excluding solely running royalties paid by Licensee to IURTC for Net Sales by Sublicensees), irrespective of whether such revenues are received in the form of cash, barter, credit, stock, warrants, release from debt, goods or services, licenses back, and/or a premium on the sale of equity (i.e., payments for equity that exceed the pre-Sublicense value).
Sublicensing Revenue. Piramal Imaging SA shall pay AC Immune a percentage of Sublicense Revenue. Subject to Section 8.6, [*****] CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED. [*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL – [*****] Percentage of Sublicense Revenue [*****] [*****] [*****] [*****] [*****] [*****]
Sublicensing Revenue. If Roivant or its Affiliate grants a Sublicense to a Sublicensee [***] of any Licensed Product, Roivant shall pay to TheraVida [***] of all Sublicensee Revenue received from such Sublicensee. If Roivant grants a Sublicense to a Sublicensee [***] for any Licensed Product, Roivant shall pay to TheraVida [***] of all Sublicensee Revenue received from such Sublicensee. Within [***] after receipt of any Sublicensee Revenue subject to this Section 8.6 (Sublicensing Revenue), Roivant shall notify TheraVida of the receipt of such Sublicensee Revenue and the amount due to TheraVida and TheraVida shall invoice Roivant for the corresponding amount. Roivant shall remit payment to TheraVida within [***] of the receipt of such invoice.
